Alendronate for 6 or 12 months following denosumab discontinuation in women with postmenopausal osteoporosis: A prospective observational study
Clicks: 2
ID: 318320
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
0.3
/100
2 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #63 of 119 articles by views in journal of bone and mineral research : the official journal of the american society for bone and mineral research
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Unopposed denosumab (Dmab) discontinuation is followed by overshoot in bone turnover markers (BTM), rapid bone mineral density (BMD) loss, and elevated risk of multiple vertebral fractures. To preserve BMD gains and mitigate fracture risk it is currently recommended to administer bisphosphonates following Dmab discontinuation. We prospectively evaluate the efficacy of alendronate (ALN) in preventing BTM overshoot and BMD loss in women with postmenopausal osteoporosis (PMO) discontinuing Dmab. This is a 12-month prospective, observational study among patients treated with Dmab 60 mg every 6 months and achieved osteopenia at the lumbar spine (LS) and femoral neck (FN). Six months after the last Dmab injection participants received oral ALN 70 mg weekly for 6 months followed by 6 months without therapy (Group 1) or for 12 months (Group 2). The primary endpoint was the percent change in LS-BMD from baseline to month 12. Eighty women (39 Group 1, 41 Group 2) who had received 2–22 Dmab injections (mean 9.8) completed the study. Median age was 67 years; 27.5% had prevalent fractures and 59% had prior anti-osteoporotic therapy. At month 12, LS-BMD declined significantly in the overall cohort [−5.9% (8.2%), p < 0.001], with no difference between groups (Group 1: −6.8% vs Group 2: −5.0%, p = 0.50). FN-BMD decreased (−3.5%, p < 0.001), and similarly in both groups. Serum procollagen type 1 N-terminal propeptide (P1NP), C-terminal telopeptide of type 1 collagen (CTX), and tartrate-resistant acid phosphatase isoform 5b increased significantly; P1NP and CTX were significantly higher in Group 1 at month 12. One patient sustained multiple vertebral fractures (1.25%). In conclusion, alendronate did not consistently attenuate BMD loss and BTM rebound after denosumab discontinuation in women with PMO, with 6 months being as effective as 12 months of treatment. Importantly, both regimens were associated with low incidence of multiple vertebral fractures.
| Reference Key |
openalex_W7165665140
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Polyzois Makras, Athanasios D. Anastasilakis, Andrea Palermo, Anda Mihaela Naciu, Stergios A. Pοlyzos, Danai Georgakopoulou, Αθανάσιος Παπαθεοδώρου, Mathaios Savvidis, Socrates Papapoulos, Maria P. Yavropoulou |
| Journal | journal of bone and mineral research : the official journal of the american society for bone and mineral research |
| Year | 2026 |
| DOI |
10.1093/jbmr/zjag103
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.